Strategic Scientific Advisory & Fractional Leadership

Translational strategy for biotech, investors, and innovation teams building human-relevant evidence.

NAMina Bio offers founder-led scientific advisory services for early-stage biotech companies, investors, technology developers, and translational research teams seeking rigorous evaluation of preclinical strategy, advanced model systems, and data-driven development plans.

Our advisory work is designed to help organizations assess scientific risk, strengthen translational positioning, and build more credible paths from discovery-stage biology to decision-ready evidence.

Bridging Scientific Depth and Strategic Execution

The gap between promising early-stage discovery and clinically relevant evidence is one of the most critical risk points in biotechnology.

Evaluating a new asset, platform, or translational workflow requires more than a conventional review of a pitch deck or publication package. It requires an understanding of disease biology, preclinical model limitations, human-relevant systems, data quality, regulatory direction, and commercial readiness.

Led by Dr. Paola Dama, PhD, Founder & CEO of NAMina Bio, this advisory service brings together over 15 years of international experience in molecular oncology, immunotherapy, gene therapy, 3D tumor models, organoids, New Approach Methodologies, and biotech business development.

3D Tumor Model Feasibility Consultation
1 hr
Book Now
Scientific Due Diligence for Investors
1 hr
Book Now
Fractional Scientific Leadership
1 hr
Book Now
NAMs, Organoid & Preclinical Strategy
1 hr
Book Now
NAMina Program Builder™ Demo & Research Session
45 min
Book Now

Founder-Led Expertise

Dr. Paola Dama brings a rare combination of academic, industry, and entrepreneurial experience across oncology, gene therapy, immunotherapy, and advanced preclinical modeling.

Selected credentials include:

Founder & CEO, NAMina Bio Corp
BioLabs@NYU Langone resident startup footprint, New York
Former Senior Scientific Product & Business Development Manager, VectorBuilder
Visiting Research Fellow, University of Sussex
Editorial Board Member, Cancer Gene Therapy
Reviewer for leading oncology and translational journals
Recipient of Cancer Gene Therapy Reader’s Choice recognition in 2022 and 2024
Experience across pharma-sponsored immuno-oncology research, CRISPR functional genomics, viral vectors, 3D tumor biology, and translational oncology

Engagement Formats

Advisory engagements can be structured based on the level of support required.

Examples include:

One-hour strategic consultation
Scientific due-diligence review
Investor or partner-readiness audit
Fractional scientific leadership
White paper or technical narrative development
Custom advisory mandate for biotech, pharma, or investment teams

All engagements are scoped individually based on objectives, timeline, confidentiality requirements, and deliverables.

Get in Touch for Advisory Options

Available Online

3D Tumor Model Feasibility Consultation

Evaluate the right 3D model strategy for your translational research program.

1 hCustomer's Place

Service Description

A focused founder-led consultation for academic, biotech, pharma, and technology teams exploring whether a 3D tumor model, organoid, tumoroid, co-culture system, or dynamic culture workflow is appropriate for their research goals. This session helps clarify model suitability, biological relevance, assay design, technical feasibility, expected readouts, and potential development roadmap. The consultation may support early planning for drug screening, translational oncology studies, mechanism-of-action work, tumor microenvironment modeling, or human-relevant preclinical validation. Following the consultation, NAMina Bio can provide a recommended next-step strategy, including possible model architecture, workflow options, partner-enabled technologies, and project scope considerations. Final project design and pricing depend on scientific objectives, model complexity, materials, timeline, and required deliverables.